Alnylam Pharmaceuticals (ALNY) – Analysts’ Weekly Ratings Changes

Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2025 – Alnylam Pharmaceuticals was given a new $570.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
• 11/2/2025 – Alnylam Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/31/2025 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $500.00 price target on the stock.
• 10/31/2025 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $489.00 price target on the stock, up previously from $449.00.
• 10/31/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Barclays PLC from $460.00 to $527.00. They now have an “overweight” rating on the stock.
• 10/30/2025 – Alnylam Pharmaceuticals had its price target lowered by analysts at Jefferies Financial Group Inc. from $550.00 to $549.00. They now have a “buy” rating on the stock.
• 10/25/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/17/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $459.00 to $535.00. They now have a “buy” rating on the stock.
• 10/13/2025 – Alnylam Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $475.00 to $473.00. They now have an “overweight” rating on the stock.
• 10/12/2025 – Alnylam Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/10/2025 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $570.00 price target on the stock.
• 10/8/2025 – Alnylam Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $405.00 to $475.00. They now have an “equal weight” rating on the stock.
• 10/6/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $441.00 to $495.00. They now have a “buy” rating on the stock.
• 10/4/2025 – Alnylam Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/27/2025 – Alnylam Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/19/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $435.00 to $500.00. They now have an “outperform” rating on the stock.
• 9/17/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $453.00 to $520.00. They now have a “buy” rating on the stock.
• 9/16/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $504.00 to $566.00. They now have a “buy” rating on the stock.
• 9/11/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Evercore ISI from $280.00 to $515.05. They now have an “outperform” rating on the stock.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the sale, the executive vice president owned 25,231 shares in the company, valued at $11,405,673.55. This trade represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.